Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QAX576 · 6 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| QAX576 | EXPERIMENTAL | - |
| Infliximab | OTHER | - |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| QAX576 1 mg/kg | ACTIVE_COMPARATOR | - |
| QAX576 3 mg/kg | ACTIVE_COMPARATOR | - |
| QAX576 10 mg/kg | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| QAX576 | DRUG | - |
| Infliximab | DRUG | - |
| Placebo | DRUG | every 3 weeks via intravenous infusion |
| QAX576 placebo | DRUG | - |
Inclusion Criteria: * At least one draining enterocutaneous perianal fistula * Diagnosis of Crohn's disease (CD) must have been established for at least 6 months * At least one ineffective fistula treatment (but no previously failed anti-TNFα (tumour necrosis factor) antibody treatment) * Patients ...
Top 1 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150 |
QAX576 is an investigational small molecule developed by Novartis AG for respiratory and immune-related conditions. It has been studied in allergic rhinitis, asthma, Crohn's disease, eosinophilic esophagitis, and idiopathic pulmonary fibrosis. It is an IL13 inhibitor that has completed Phase 2 clinical testing.
QAX576 targets IL13, an inflammatory cytokine also known as interleukin-13. As an IL13 inhibitor, QAX576 is designed to block the activity of this signaling protein, which is involved in allergic and eosinophilic inflammatory responses. This mechanism underlies its study in asthma, eosinophilic esophagitis, and related conditions.
QAX576 is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the clinical trial program evaluating the compound across multiple inflammatory and respiratory indications, including asthma, Crohn's disease, and eosinophilic esophagitis.
QAX576 has completed Phase 2 clinical development. It is an investigational agent and is not described as approved for any indication. The Phase 2 program covered asthma, Crohn's disease, and eosinophilic esophagitis, with a Phase 1 study also completed in asthma patients.
QAX576 has been evaluated in completed trials including NCT01130064 in asthma, NCT01355614 in fistulizing Crohn's disease, NCT01022970 in eosinophilic esophagitis, and NCT00940160, a Phase 1 asthma study. These trials enrolled a combined total of 324 participants across the United States, Europe, Russia, and Argentina.
QAX576 is not described as approved and remains an investigational drug that has completed Phase 2 testing. Its trials were randomized, double-blind, and placebo-controlled, but no regulatory approval for any indication is stated. Development status should be confirmed through current regulatory filings.